Study of the Anti-tumoral Immune Response
Not Applicable
Completed
- Conditions
- GliomaBreast Cancer
- Registration Number
- NCT02854644
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Brief Summary
This study evaluates the frequency of the spontaneous T cells specific CD4 answers of tumoral antigens breast cancer and glioma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 167
Inclusion Criteria
- Performance status 0,1 or 2
- breast cancer or glioma
- Arm glioma: patients without anti-tumoral treatment
- Arm breast cancer: inclusion before treatment
- Arm breast cancer HER2: patients with current therapy
Exclusion Criteria
- Psychiatric disease compromising the understanding of the information or the realization of the study
- vulnerable People according to the law (minors, adults under protection, private persons of freedom ...)
- Unaffiliated People to the Social Security
- People being for the period of exclusion from another study
- Life expectancy estimated unless 3 months.
- For patients in Arm glioma: patients having already begun a systematic treatment.
- For patients with a breast cancer: patient already under current therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Spontaneous immune responses of T cells CD4 specific tumor antigens 15 months
- Secondary Outcome Measures
Name Time Method T cells level 15 months
Trial Locations
- Locations (1)
Centre Hospitalier Régional Universitaire
🇫🇷Besançon, France
Centre Hospitalier Régional Universitaire🇫🇷Besançon, France